EUVIMEDEUVIMED entdecken
Open Access

Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes

Alexander Kutz, Dae Hyun Kim, Deborah J Wexler, Jun Liu, Sebastian Schneeweiss, Robert J Glynn, Elisabetta Patorno iD

Diabetes Care · 01.11.2023 · 46 (11) · 2004-2014

DOI: 10.2337/dc23-0671 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes Care, online erschienen am 07.09.2023. Verfasst von Alexander Kutz und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors, Sodium-Glucose Transporter 2 Inhibitors, Frailty. Die Arbeit wurde bisher 75-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, FDA HHS, Novo Nordisk.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE To evaluate the comparative cardiovascular effectiveness and safety of sodium–glucose cotransporter 2 inhibitors (SGLT-2is), glucagon-like peptide 1 receptor agonists (GLP-1RAs), and dipeptidyl peptidase 4 inhibitors (DPP-4is) in older adults with type 2 diabetes (T2D) across different frailty strata. RESEARCH DESIGN AND METHODS We performed three 1:1 propensity score–matched cohort studies, each stratified by three frailty strata, using data from Medicare beneficiaries (2013–2019) with T2D who initiated SGLT-2is, GLP-1RAs, or DPP-4is. In time-to-event analyses, we assessed the primary cardiovascular effectiveness composite outcome of acute myocardial infarction, ischemic stroke, hospitalization for heart failure, and all-cause mortality. The primary safety outcome was a composite of severe adverse events that have been linked to SGLT-2i or GLP-1RA use. RESULTS Compared with DPP-4is, the overall hazard ratio (HR) for the primary effectiveness outcome associated with SGLT-2is (n = 120,202 matched pairs) was 0.72 (95% CI 0.69–0.75), corresponding to an incidence rate difference (IRD) of −13.35 (95% CI −15.06 to −11.64). IRD ranged from −6.74 (95% CI −8.61 to −4.87) in nonfrail to −27.24 (95% CI −41.64 to −12.84) in frail people (P for interaction < 0.01). Consistent benefits were observed for GLP-1RAs compared with DPP-4is (n = 113,864), with an overall HR of 0.74 (95% CI 0.71–0.77) and an IRD of −15.49 (95% CI −17.46 to −13.52). IRD in the lowest frailty stratum was −7.02 (95% CI −9.23 to −4.81) and −25.88 (95% CI −38.30 to −13.46) in the highest (P for interaction < 0.01). Results for SGLT-2is versus GLP-1RAs (n = 89,865) were comparable. Severe adverse events were not more frequent with SGLT-2is or GLP-1RAs than DPP-4is. CONCLUSIONS SGLT-2is and GLP-1RAs safely improved cardiovascular outcomes and all-cause mortality, with the largest absolute benefits among frail people.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsSodium-Glucose Transporter 2 InhibitorsFrailtyMyocardial InfarctionAgedHumansUnited StatesHypoglycemic AgentsMedicareGlucagon-Like Peptide-1 Receptor Agonists

Substanzen

Dipeptidyl-Peptidase IV InhibitorsSodium-Glucose Transporter 2 InhibitorsHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
  • Marcus Institute for Aging Research, Hebrew SeniorLife, Boston, MA.
  • Division of Gerontology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA.
  • Massachusetts General Hospital Diabetes Center and Harvard Medical School, Boston, MA.

ORCID-Profile: Elisabetta Patorno

Förderung

  • NIA NIH HHS
  • FDA HHS
  • Novo Nordisk
  • Harvard Medical School
  • Swiss National Science Foundation
  • National Institute on Aging
  • Patient Centered Outcomes Research Institute
  • Brigham and Women's Hospital

Zitieren

APA

Kutz, A., Kim, D. H., Wexler, D. J., Liu, J., Schneeweiss, S., Glynn, R. J., & Patorno, E. (2023). Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes. Diabetes Care, 46(11), 2004-2014. https://doi.org/10.2337/dc23-0671

Vancouver

Kutz A, Kim DH, Wexler DJ, Liu J, Schneeweiss S, Glynn RJ, et al. Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes. Diabetes Care. 2023;46(11):2004-2014. doi:10.2337/dc23-0671

BibTeX
@article{Kutz2023,
  author = {Kutz, Alexander and Kim, Dae Hyun and Wexler, Deborah J and Liu, Jun and Schneeweiss, Sebastian and Glynn, Robert J and Patorno, Elisabetta},
  title = {Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes},
  journal = {Diabetes Care},
  year = {2023},
  volume = {46},
  number = {11},
  pages = {2004--2014},
  doi = {10.2337/dc23-0671}
}
Kostenlos starten →